每經AI快訊，藥明康德（SH 603259，收盤價(jia)：69.8元）10月12日晚(wan)間發布業(ye)(ye)(ye)(ye)(ye)(ye)績預(yu)告(gao)，公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)預(yu)計(ji)(ji)2022年(nian)前三(san)季度(du)實(shi)現(xian)(xian)歸屬(shu)于公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)股東的(de)(de)(de)凈(jing)利(li)潤約(yue)人(ren)民(min)幣約(yue)73.78億(yi)元，較上(shang)年(nian)同(tong)期(qi)人(ren)民(min)幣約(yue)35.62億(yi)元，同(tong)比(bi)增(zeng)(zeng)(zeng)長(chang)約(yue)107.12%；本(ben)(ben)期(qi)基(ji)本(ben)(ben)每股收益(yi)預(yu)計(ji)(ji)約(yue)人(ren)民(min)幣2.52元，較上(shang)年(nian)同(tong)期(qi)人(ren)民(min)幣1.22元，同(tong)比(bi)增(zeng)(zeng)(zeng)長(chang)約(yue)106.56%。業(ye)(ye)(ye)(ye)(ye)(ye)績變動主要原因(yin)是，主營(ying)(ying)業(ye)(ye)(ye)(ye)(ye)(ye)務(wu)(wu)影響。公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)預(yu)計(ji)(ji)2022年(nian)前三(san)季度(du)實(shi)現(xian)(xian)營(ying)(ying)業(ye)(ye)(ye)(ye)(ye)(ye)收入(ru)同(tong)比(bi)增(zeng)(zeng)(zeng)長(chang)約(yue)71.87%。公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)持續強(qiang)化(hua)(hua)藥明康德獨特的(de)(de)(de)一體(ti)化(hua)(hua)CRDMO和CTDMO業(ye)(ye)(ye)(ye)(ye)(ye)務(wu)(wu)模式(shi)；在多地疫情(qing)持續反(fan)復的(de)(de)(de)影響下，充(chong)分發揮全球布局、多地運營(ying)(ying)及(ji)全產業(ye)(ye)(ye)(ye)(ye)(ye)鏈覆(fu)蓋的(de)(de)(de)優勢(shi)，及(ji)時(shi)制定(ding)并高效執(zhi)行業(ye)(ye)(ye)(ye)(ye)(ye)務(wu)(wu)連續性計(ji)(ji)劃，確保公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)整(zheng)(zheng)體(ti)業(ye)(ye)(ye)(ye)(ye)(ye)績目標的(de)(de)(de)達(da)成。公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)對于達(da)成2022年(nian)全年(nian)收入(ru)增(zeng)(zeng)(zeng)長(chang)目標68-72%充(chong)滿信心(xin)。公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)預(yu)計(ji)(ji)2022年(nian)前三(san)季度(du)實(shi)現(xian)(xian)經調(diao)(diao)整(zheng)(zheng)非(fei)《國際財務(wu)(wu)報(bao)告(gao)準則》下歸屬(shu)于公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)股東的(de)(de)(de)凈(jing)利(li)潤同(tong)比(bi)增(zeng)(zeng)(zeng)長(chang)約(yue)77.92%。公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)通過(guo)不(bu)斷優化(hua)(hua)經營(ying)(ying)效率，產能利(li)用率持續提升，規模效應(ying)得以(yi)進一步(bu)顯現(xian)(xian)，使得經調(diao)(diao)整(zheng)(zheng)非(fei)《國際財務(wu)(wu)報(bao)告(gao)準則》下歸屬(shu)于公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)股東的(de)(de)(de)凈(jing)利(li)潤增(zeng)(zeng)(zeng)速超過(guo)同(tong)期(qi)收入(ru)增(zeng)(zeng)(zeng)長(chang)速度(du)。公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)認為經調(diao)(diao)整(zheng)(zheng)的(de)(de)(de)財務(wu)(wu)指(zhi)標有助了解及(ji)評估公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)的(de)(de)(de)業(ye)(ye)(ye)(ye)(ye)(ye)務(wu)(wu)表(biao)現(xian)(xian)及(ji)經營(ying)(ying)趨勢(shi)。

2022年(nian)1至(zhi)6月份(fen)，藥(yao)明康(kang)德的營業(ye)收(shou)入構成為：化學業(ye)務(WuXiChemistry)占(zhan)(zhan)比(bi)73.07%，測試業(ye)務(WuXiTesting)占(zhan)(zhan)比(bi)14.67%，生物(wu)學業(ye)務(WuXiBiology)占(zhan)(zhan)比(bi)6.14%，細胞(bao)及基(ji)因療法CTDMO業(ye)務(WuXiATU)占(zhan)(zhan)比(bi)3.47%，國內新藥(yao)研發服務部(bu)(WuXiDDSU)占(zhan)(zhan)比(bi)2.56%。

藥明(ming)康德的董事長、總裁均是(shi)Ge Li(李(li)革(ge))，男，55歲(sui)，學歷背景為博士。

截至發稿，藥明康德市(shi)值(zhi)為2066億元。

道達號（daoda1997）“個股趨(qu)勢”提醒：
1. 藥明康德近30日內北向資金持股量減少2887.06萬股，占流通股比例減少1.12%；
2. 近30日內無機構對藥明康德進行調研。
更多個股趨(qu)勢信息，請搜索微信公(gong)眾號(hao)“道(dao)達號(hao)”，回復“查詢”，領取免費查詢權限！

每經頭條(tiao)（nbdtoutiao）——

(記者 曾健輝)

免責(ze)聲明：本文內(nei)容與(yu)數據僅供參考，不構成投資建議，使用前(qian)請核實。據此操作，風險自擔。